Essex Bio-Technology (HKG:1061) said the anti-VEGF ophthalmic injection bio-pharmaceutical product, HLX04-O, co-developed by two of its subsidiaries and Shanghai Henlius Biotech (HKG:2696), saw the last visit of the last patient (LPLV) for its phase 3 clinical study.
The study is a randomized, double-blinded, active-controlled, and global study conducted in patients with exudative age-related macular degeneration or wet-AMD, a Monday Hong Kong bourse filing said.
The drug is a new ophthalmic preparation product and is planned to be used for the treatment of wet-AMD in China.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。